TG Therapeutics Inc TGTX.OQ TGTX.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024
The Morrisville North Carolina-based company is expected to report a 127.3% increase in revenue to $99.954 million from $43.97 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for TG Therapeutics Inc is for earnings of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for TG Therapeutics Inc is $43.00, above its last closing price of $28.53.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 0.04 | 0.03 | 0.02 | Missed | -32.2 |
Jun. 30 2024 | -0.05 | -0.05 | 0.04 | Beat | 187.5 |
Mar. 31 2024 | -0.02 | -0.04 | -0.07 | Missed | -96 |
Dec. 31 2023 | -0.12 | -0.10 | -0.10 | Met | 4.1 |
Sep. 30 2023 | 0.05 | 0.12 | 0.73 | Beat | 530.9 |
Jun. 30 2023 | -0.24 | -0.25 | -0.34 | Missed | -36.7 |
Mar. 31 2023 | -0.38 | -0.37 | -0.28 | Beat | 23.7 |
Dec. 31 2022 | -0.28 | -0.26 | -0.39 | Missed | -50 |
This summary was machine generated February 28 at 14:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。